Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Bharathi Muthusamy"'
Autor:
Bharathi Muthusamy, Kira Raskina, Katherine T. Lofgren, Gerald Li, Khaled Tolba, Karen Schwed, Emily Castellanos, Richard S.P. Huang, Geoffrey R. Oxnard, Alexa B. Schrock, Nathan Pennell
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
Tyrosine kinase inhibitors and immune checkpoint inhibitors (ICI), each requiring testing for precision biomarkers, have recently been approved in the adjuvant setting. We assessed the potential value of multi-gene testing in early lung adenocarcinom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe09fbdabd8cd8950a18923fd89bee4c
https://pubmed.ncbi.nlm.nih.gov/36494074
https://pubmed.ncbi.nlm.nih.gov/36494074
Autor:
Bharathi Muthusamy, Nathan Pennell
Publikováno v:
Journal of Thoracic Oncology. 17:179-181
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::374cec27247401998335015bd8c79d2a
https://doi.org/10.1016/j.jtho.2021.11.012
https://doi.org/10.1016/j.jtho.2021.11.012
Publikováno v:
Journal of the National Comprehensive Cancer Network : JNCCN. 20(8)
Despite remarkable treatment advancements in patients with advanced non–small cell lung cancer (NSCLC), recurrence rates for those with resectable, early-stage disease remains high. Immune checkpoint inhibitors and targeted therapies are 2 promisin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3338fef7cdd1a09e23f6b7569196aa59
https://pubmed.ncbi.nlm.nih.gov/35948038
https://pubmed.ncbi.nlm.nih.gov/35948038
Publikováno v:
Clinical lung cancer. 23(2)
Surgery is the best option for patients with early stage non-small cell lung cancer (NSCLC). However, the rate of local and metastatic recurrences following surgery alone is high, especially in NSCLC patients with N2 lymph node involvement. A recent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9779ec8ef584ac0097558b439aa471c
https://pubmed.ncbi.nlm.nih.gov/34952792
https://pubmed.ncbi.nlm.nih.gov/34952792
Autor:
Nathan A. Pennell, Liangliang Zhang, Katherine T Lofgren, Bharathi Muthusamy, Emily Castellanos, Karen Schwed, Olivier Humblet, Alexa Betzig Schrock, Geoffrey R. Oxnard
Publikováno v:
Journal of Clinical Oncology. 40:8525-8525
8525 Background: Resected early-stage NSCLC has high risk of recurrence, and tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICI), each requiring testing for precision biomarkers, have recently been approved in the adjuvant (adj)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::322ddb03db5f6264edd625dec5359098
https://doi.org/10.1200/jco.2022.40.16_suppl.8525
https://doi.org/10.1200/jco.2022.40.16_suppl.8525
Autor:
Shubha Shankaranarayana, Victoria DeVincenzo, Eric Hansen, Nathan A. Pennell, Ming He, Bharathi Muthusamy, Ching-Kun Wang, Andrew J. Belli
Publikováno v:
Journal of Clinical Oncology. 39:e21156-e21156
e21156 Background: The identification of driver mutations and development of targeted therapies have significantly improved outcomes of patients with advanced non-small cell lung cancer (aNSCLC). It has been shown in clinical trials that immunotherap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ffbbdad15156ce0d8e2e62866b2e44a2
https://doi.org/10.1200/jco.2021.39.15_suppl.e21156
https://doi.org/10.1200/jco.2021.39.15_suppl.e21156
Autor:
Gajendra P. Narwane, Bharathi Muthusamy, Venkateswarlu Yadavalli, M. S. R. Krishna, Nagarajan Pothi
Publikováno v:
Rice Science, Vol 19, Iss 1, Pp 70-74 (2012)
Brown planthopper (Nilaparvata lugens Stål) is one of the most damaging pests causing hopper burn in rice, and thereby reducing the productivity and also the quality of the product. The effective management strategy to control this pest is the ident
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6473697f631e7ce5fdd122576acefb09
http://www.sciencedirect.com/science/article/pii/S1672630812600237
http://www.sciencedirect.com/science/article/pii/S1672630812600237
Autor:
Marwan Ghabril, Naga Chalasani, Eric S. Orman, Raj Vuppalanchi, Craig Lammert, Bharathi Muthusamy, Lori Curtis
Publikováno v:
Gastroenterology. 150:S337
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::acc89fe373901bb0431e4dea765a44d8
https://doi.org/10.1016/s0016-5085(16)31184-2
https://doi.org/10.1016/s0016-5085(16)31184-2
Autor:
Margaret C Keller, Parameswaran Venugopal, Jamile M. Shammo, Melissa L. Larson, Bharathi Muthusamy, Sheena Sahota, Allison Zindell, Stephanie A. Gregory
Publikováno v:
Blood. 116:1069-1069
Abstract 1069 Background: Cytogenetic data plays an important role in assessing prognosis and determining choice of therapy for AML. Traditionally, patients with AML are treated with infusional cytarabine and an anthracycline. CR rates with this regi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::53e2667df3ec8d9bb55d8a0cb01ce548
https://doi.org/10.1182/blood.v116.21.1069.1069
https://doi.org/10.1182/blood.v116.21.1069.1069
Autor:
Bharathi Muthusamy, Stephanie A. Gregory, Parameswaran Venugopal, Margaret C Keller, Sheena Sahota, Melissa L. Larson, Jamile M. Shammo, Allison Zindell
Publikováno v:
Blood. 116:1068-1068
Abstract 1068 Background: Patients with AML who are eligible for chemotherapy are traditionally treated with infusional cytarabine and an anthracycline. CR rates with this combination have been approximately 50–60% with an induction mortality of 10
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::12630ad366c4fde341c394067d9da773
https://doi.org/10.1182/blood.v116.21.1068.1068
https://doi.org/10.1182/blood.v116.21.1068.1068